267 completed. 267 Phase 2, 35 Phase 1, 6 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 267 | Completed 267 |
| Phase 1 | 35 | Completed 35 |
| Phase 3 | 6 | Completed 6 |
Follow Dermatitis, Atopic: new trials by email Literature Review of Dermatitis, Atopic trials Research Report on Dermatitis, Atopic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2b Study of EVO756 in Adults With Atopic Dermatitis EVO756, Placebo control - Atopic Dermatitis | Phase 2 | Completed | Evommune, Inc. | 121 | 2025-08-26 | 2026-10-05 |
| A Study of MG-K10 Humanized Monoclonal Antibody Injection in Subjects With Atopic Dermatitis MG-K10/Placebo - Atopic Dermatitis (AD) | Phase 2 | Completed | Shanghai Mabgeek Biotech.Co.Ltd | 60 | 2025-06-30 | 2026-08-03 |
| Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis ARQ-151 cream 0.05% - Atopic Dermatitis (Eczema) | Phase 2 | Completed | Arcutis Biotherapeutics, Inc. | 101 | 2025-06-09 | 2025-12-10 |
| Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis VC005 Placebo group, VC005 groups - Atopic Dermatitis | Phase 2 | Completed | Jiangsu vcare pharmaceutical technology co., LTD | 118 | 2025-04-28 | 2026-04-13 |
| A Study to Assess Efficacy and Safety of CGB-500, 1% Tofacitinib Versus an Active Comparator for Atopic Dermatitis CGB-500 Ointment with 1% tofacitinib, Ruxolitinib 1.5% Cream QD - Atopic Dermatitis (AD) | Phase 2 | Completed | CAGE Bio Inc. | 3 | 2025-04-21 | 2026-04-01 |
| A Study to Evaluate the Efficacy and Safety of LNK01004 Ointment in Adults With Atopic Dermatitis LNK01004 ointment 0.3%, LNK01004 ointment 1.0%, Vehicle - Atopic Dermatitis | Phase 2 | Completed | Lynk Pharmaceuticals Co., Ltd | 75 | 2025-03-18 | 2026-01-14 |
| Efficacy Study of EVO301 in Moderate to Severe Atopic Dermatitis EVO301, Placebo - Atopic Dermatitis (AD), Eczema | Phase 2 | Completed | Evommune, Inc. | 71 | 2025-02-13 | 2025-12-04 |
| A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis Lunsekimig, Placebo - Dermatitis Atopic | Phase 2 | Completed | Sanofi | 150 | 2025-01-30 | 2026-04-21 |
| Phase 2b Safety and Efficacy Study of CGB-500 Topical Ointment With 0.5% and 1% Tofacitnib for Treatment of Atopic Dermatitis CGB-500 with 0.5% tofacitinib, CGB-500 Ointment with 1% tofacitinib, Vehicle (placebo) - Atopic Dermatitis (AD) | Phase 2 | Completed | CAGE Bio Inc. | 180 | 2024-12-18 | 2026-04-02 |
| Study of ATI-2138 in Adult Participants With Moderate to Severe Atopic Dermatitis ATI-2138 - Atopic Dermatitis | Phase 2 | Completed | Aclaris Therapeutics, Inc. | 14 | 2024-08-19 | 2026-03-12 |
| Evaluation of 611 in Chinese Children and Adolescents With Moderate to Severe Atopic Dermatitis Recombinant Anti-interleukin-4 Receptor Alpha Monoclonal Antibody Injection (611) - Dermatitis, Atopic | Phase 1 / Phase 2 | Completed | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 128 | 2024-07-10 | 2026-07-01 |
| A Study to Evaluate the Efficacy and Safety of AK120 in Subjects With Moderate to Severe Atopic Dermatitis AK120 300mg Q2W (JAK inhibitor users need to double the initial dose) - Atopic Dermatitis | Phase 2 | Completed | Akeso | 450 | 2024-07-08 | 2026-03-17 |
| Topical YR001 Ointment in Adult With Mild to Moderate Atopic Dermatitis YR001 ointment, Placebo - Atopic Dermatitis | Phase 2 | Completed | Hangzhou Yirui Pharmaceutical Technology Co., Ltd | 35 | 2024-06-19 | 2025-12-18 |
| Efficacy, Safety, and Tolerability of Abrocitinib in Subjects With Moderate to Severe Chronic Hand Eczema Refractory to Corticosteroid Therapy Abrocitinib 200 mg, Abrocitinib 100 mg, Placebo - Chronic Hand Eczema | Phase 2 | Completed | Innovaderm Research Inc. | 82 | 2024-05-31 | 2026-02-03 |
| A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis Camoteskimab, Placebo - Atopic Dermatitis, Atopic | Phase 2 | Completed | Apollo Therapeutics Ltd | 62 | 2024-05-01 | 2025-09-18 |
| Study of TDM-180935 in Atopic Dermatitis Patients TDM-180935 topical ointment 1.0%, TDM-180935 topical ointment 2.0%, TDM-180935 topical vehicle ointment 1 - Atopic Dermatitis | Phase 2 | Completed | Technoderma Medicines Inc. | 24 | 2024-04-13 | 2025-04-24 |
| Phase 2 Trial of HY209gel in Atopic Dermatitis Patients HY209GEL Active, Placebo - Atopic Dermatitis, Atopic Dermatitis Eczema | Phase 2 | Completed | Shaperon | 210 | 2024-03-01 | 2026-06-24 |
| Study of CM310 in Children Subjects With Moderate-to-severe Atopic Dermatis CM310 - Atopic Dermatitis | Phase 1 / Phase 2 | Completed | Keymed Biosciences Co.Ltd | 24 | 2023-12-22 | 2024-10-15 |
| A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis CM310 - Atopic Dermatitis | Phase 2 | Completed | Keymed Biosciences Co.Ltd | 263 | 2023-12-21 | 2026-08-20 |
| Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis) OpSCF, Placebo - Atopic Dermatitis | Phase 2 | Completed | Insmed Incorporated | 50 | 2023-11-21 | 2026-09-11 |
Showing 20 of 267. Sign in to see all of them.
Eczema (63) · Pruritus (18) · Skin Diseases (15) · Dermatitis (11) · Skin Diseases, Eczematous (4) · Hypersensitivity (3) · Immune System Diseases (3) · Psoriasis (3) · Hypersensitivity, Immediate (2) · Skin Diseases, Genetic (2) · Acne Vulgaris (1) · Alopecia Areata (1) · Asthma (1) · Autoimmune Diseases (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (267) · Genetic Diseases, Inborn (266) · Skin and Connective Tissue Diseases (266) · Hypersensitivity, Immediate (265) · Skin Diseases, Genetic (265) · Hypersensitivity (264) · Immune System Diseases (264) · Skin Diseases, Eczematous (263) · Dermatitis (256) · Skin Diseases (252) · Pathological Conditions, Signs and Symptoms (20) · Signs and Symptoms (18) · Skin Manifestations (18) · Skin Diseases, Papulosquamous (5) · Infections (4)
dupilumab (8) · Ointments (7) · nemolizumab (6) · R-1,1,1-trifluoro-4-(5-fluoro-2,3-dihydrobenzofuran-7-yl)-4-methyl-2-(((2-methyl-5-quinolyl)amino)methyl)pentan-2-ol (5) · Exercise (4) · apremilast (4) · difamilast (4) · methyl 4-(((3-(6,7-dimethoxy-2-(methylamino)quinazolin-4-yl)phenyl)amino)carbonyl)benzoate (4) · tofacitinib (4) · abrocitinib (3) · lebrikizumab (3) · ruxolitinib (3) · tapinarof (3) · tralokinumab (3) · BID protein, human (2)
Pfizer (11) · LEO Pharma (8) · Bayer (7) · Galderma R&D (7) · Regeneron Pharmaceuticals (7) · Keymed Biosciences Co.Ltd (6) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Aclaris Therapeutics, Inc. (4) · Astellas Pharma Inc (4) · DS Biopharma (4) · Organon and Co (4) · Sanofi (4) · Akeso (3) · Amorepacific Corporation (3) · CAGE Bio Inc. (3)
United States (139) · Canada (66) · Germany (53) · Poland (36) · Australia (28) · Japan (27) · China (26) · United Kingdom (25) · Czechia (15) · Hungary (14) · Spain (12) · France (10) · Netherlands (9) · South Korea (9) · Taiwan (9)
Eric Simpson, MD (2) · James Lee, MD, PhD (2)
PMID 25006719, PMID 16895558, PMID 21039597, PMID 21771098, PMID 22508772, PMID 22948032, PMID 23638978, PMID 23768574, PMID 24284985, PMID 24331381, PMID 26439129, PMID 26454361, PMID 26461821, PMID 26527564, PMID 26569624, PMID 26581111, PMID 26618557, PMID 26777100, PMID 27268421, PMID 28249150, PMID 28403910, PMID 28845523, PMID 29567358, PMID 29753033, PMID 29906525, PMID 30194992, PMID 30528828, PMID 30556911, PMID 30738171, PMID 30909923, PMID 31252032, PMID 31419544, PMID 31449914, PMID 31577341, PMID 31595499, PMID 31629805, PMID 31786154, PMID 31838180, PMID 32101256, PMID 32315497, PMID 32936233, PMID 33165005, PMID 33333295, PMID 33619370, PMID 33795561, PMID 33826132, PMID 33954933, PMID 33982267, PMID 34374027, PMID 34406619
2018 (6), 2016 (4), 2014 (3), 2015 (2), 2019 (2), 2008 (1), 2009 (1), R33AR077495 (1)